Maxine X. Patel MBBS, BSc, MSc, FRCP, MD

Dr. Patel is a Consultant Psychiatrist at Oxleas NHS Foundation Trust and Honorary Clinical Senior Lecturer at the Institute of Psychiatry, Psychology, and Neuroscience, King's College London. Her main research interest is in pharmacoepidemiology for psychiatry and her work aims to assess antipsychotic effectiveness as seen in routine clinical practice and to examine reasons why this differs from the efficacy of antipsychotics seen in clinical trials.

Thus she has examined the role of the drug formulation, the utility of drug plasma level monitoring, aspects of clinical trial and observational study methodology, and attitudes and preferences of both patients and health care professionals. Dr. Patel is a co-author for the British Association for Psychopharmacology consensus guidelines on (i) schizophrenia and antipsychotic medication, (ii) the management of weight gain, metabolic disturbances, and cardiovascular risk associated with psychosis and antipsychotic drug treatment. She is the joint first author for the BAP-NAPICU consensus guidelines on the clinical management of acute disturbance (de-escalation and rapid tranquillization). Previously she has been a member of the Council and also the Honorary General Secretary for the BAP. In the past 3 years, Dr. Patel has received consultancy fees and/or lecturing honoraria from Boehringer-Ingelheim, Janssen, Lundbeck, Otsuka, and Sunovion, and is currently working on clinical studies or trials for Lundbeck and Takeda.